Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recruitment Status
ACTIVE, NOT RECRUITING - HAS RESULTS
(See Contacts and Locations)Verified February 2026 by National Cancer Institute (NCI)
Sponsor
National Cancer Institute (NCI)
Information Provided by (Responsible Party)
National Cancer Institute (NCI)
Clinicaltrials.gov Identifier
NCT02502266
Other Study ID Numbers:
NCI-2015-00651
First Submitted
July 16, 2015
First Posted
July 19, 2015
Results First Posted
October 10, 2024
Last Update Posted
April 28, 2026
Last Verified
February 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

PRIMARY OBJECTIVES:

I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by overall survival (OS) and PFS, as compared to physician's choice standard of care chemotherapy in women with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE). (Phase II and Phase III) III. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by ORR as compared to physician's choice standard of care chemotherapy in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OBJECTIVES WITH INTEGRATED BIOMARKERS:

I. To assess correlation of homologous recombination deficiency (HRD) status, as assessed via BROCA-HR assay with response, as measured by PFS and ORR. (Phase II) II. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase II) III. To evaluate quality of life data compliance, as measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI) for utilization and analysis in the Phase III study. (Phase II) IV. To assess correlation of HRD status, as assessed via BROCA-HR assay with response, as measured by OS, PFS and ORR. (Phase III) V. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase III) VI. To assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

EXPLORATORY OBJECTIVES:

I. To assess exploratory biomarkers of potential HRD, including genomic scarring, BRCA1 methylation, BRCA1 protein expression, and mutations in NHEJ, and other genes that might modify HRD. (Phase II and Phase III) II. To evaluate the prognostic and predictive role of angiogenic biomarkers, as assessed by the Duke plasma angiome. (Phase II and Phase III) III. To assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/GOG-Ntx-4, and health utility as measured by the EQ-5D, of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OUTLINE:

PHASE II: Patients are randomized to 1 of 4 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel intravenously (IV) over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo computed tomography (CT) and magnetic resonance imaging (MRI) throughout the study. (12/05/2016)

ARM II (CEDIRANIB MALEATE AND OLAPARIB): Patients receive cediranib maleate orally (PO) once daily (QD) and olaparib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM III (CEDIRANIB): Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM IV (OLAPARIB): Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).

PHASE III: Patients are randomized to 1 of 3 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)

ARM II (CEDIRANIB AND OLAPARIB): Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.

ARM III (SINGLE AGENT): Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for up to 3 years.

Condition or DiseaseIntervention/Treatment
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Procedure: Computed TomographyDrug: CediranibDrug: CediranibProcedure: Computed TomographyProcedure: Computed TomographyDrug: CediranibDrug: Cediranib

Study Design

Study TypeInterventional
Actual Enrollment582 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Study Start DateMay 2, 2016
Actual Primary Completion DateJune 11, 2023
Actual Study Completion Date9mos 1w from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Phase II Arm I (reference regimen)
Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
Procedure: Computed Tomography
Undergo CT
Phase II Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
Drug: Cediranib
Given PO
Phase II Arm III (cediranib maleate)
Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
Drug: Cediranib
Given PO
Phase II Arm IV (olaparib)
Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
Procedure: Computed Tomography
Undergo CT
Phase III Arm I (reference regimen)
Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
Procedure: Computed Tomography
Undergo CT
Phase III Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
Drug: Cediranib
Given PO
Phase III Arm III (single-agent cediranib maleate)
Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
Drug: Cediranib
Given PO

Outcome Measures

Primary Outcome Measures
  1. Progression-free Survival (PFS) (Phase II Only)
    Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
  2. Progression-free Survival (PFS) (Phase III Only)
    Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
  3. Overall Survival (OS) (Phase III Only)
    Overall survival will be evaluated. To allow for better understanding of time to subsequent therapy and OS, patients on experimental study drug(s) or standard chemotherapy arm will be followed after progression, with data capture to include the date of initiation of the subsequent therapy, detailed information on the type of subsequent therapy received, and time to progression on the subsequent therapy.
Secondary Outcome Measures
  1. Objective Response Rate (Complete Response and Partial Response) (Phase II Only)
    The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR.
  2. Objective Response Rate (Complete Response and Partial Response for Phase III Only)
    The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR.
  3. Incidence of Grade 3 (or Higher) Adverse Events
    Adverse events will be categorized by CTCAE V4.0. This outcome will report the count of participants who experienced a grade 3 (or higher) adverse event.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyFemale
Accepts Healthy VolunteersNo
Inclusion Criteria
Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory
Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA rearrangement is required (12/05/2016); a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance \[VUS\] or negative) reports will be requested but not required for study enrollment
Patients should have recurrent platinum-resistant or- refractory disease - defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only is not considered as platinum-resistant or refractory disease (12/05/2016)
Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable (12/05/2016)
Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen \[CA\]125 \>= 2 x upper limit of normal \[ULN\])
No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit (12/05/2016)
Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed
Patients may not have previously received a PARP-inhibitor
Patient must have provided study specific informed consent prior to study entry
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2
Absolute neutrophil count \>= 1,500/mcL (12/05/2016)
Platelets \>= 100,000/mcL (12/05/2016)
Hemoglobin \>= 10 g/dL (12/05/2016)
Total bilirubin within =\< 1.5 times the upper limit of normal (ULN) institutional limits (12/05/2016)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT must be =\< 5 times institutional ULN (12/05/2016)
Creatinine =\< 1.5 x the institutional ULN (12/05/2016)
Urine protein: creatinine ratio urine protein creatinine (UPC) of =\< 1 OR less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of =\< 500 mg over 24 hours (12/05/2016)
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair.
Adequately controlled blood pressure (systolic blood pressure \[SBP\] =\< 140; diastolic blood pressure \[DBP\] =\< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =\< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms (12/05/2016)
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits (12/05/2016)
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
Age \>= 18 years
Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Olaparib adversely affects embryofetal survival and development in the rat; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of olaparib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Exclusion Criteria
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions (12/05/2016)
Any other investigational agents within the past 4 weeks
Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed
Prior use of PARP-inhibitors
CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs
History of intra-abdominal abscess within the past 3 months
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula (12/05/2016)
Dependency on IV hydration or total parenteral nutrition (TPN)
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:
Treated limited stage basal cell or squamous cell carcinoma of the skin
Carcinoma in situ of the breast or cervix
Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions (12/05/2016)
Prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug
Patients with any of the following:
History of myocardial infarction within six months
Unstable angina
Resting electrocardiogram (ECG) with clinically significant abnormal findings
New York Heart Association functional classification of III or IV
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or \< 55%, if threshold for normal not otherwise specified by institutional guidelines
Patients with the following risk factors should have a baseline cardiac function assessment:
Prior treatment with anthracyclines
Prior treatment with trastuzumab
Prior central thoracic radiation therapy (RT), including RT to the heart
History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
Prior history of impaired cardiac function
History of stroke or transient ischemic attack within six months
Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements (12/05/2016)
Known human immunodeficiency virus (HIV)-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible
Strong inhibitors and inducers of UGT/PgP should be used with caution (12/05/2016)
Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study

Contacts and Locations

Sponsors and CollaboratorsNational Cancer Institute (NCI)
Locations
University of Alabama at Birmingham Cancer Center | Birmingham Alabama, United States, 35233Alaska Women's Cancer Care | Anchorage Alaska, United States, 99508Providence Alaska Medical Center | Anchorage Alaska, United States, 99508University of Arkansas for Medical Sciences | Little Rock Arkansas, United States, 72205Sutter Auburn Faith Hospital | Auburn California, United States, 95602Alta Bates Summit Medical Center-Herrick Campus | Berkeley California, United States, 94704Mercy San Juan Medical Center | Carmichael California, United States, 95608Mercy Cancer Center - Elk Grove | Elk Grove California, United States, 95758Marin Cancer Care Inc | Greenbrae California, United States, 94904UC San Diego Moores Cancer Center | La Jolla California, United States, 92093Palo Alto Medical Foundation-Camino Division | Mountain View California, United States, 94040Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View California, United States, 94040Kaiser Permanente-Oakland | Oakland California, United States, 94611Palo Alto Medical Foundation Health Care | Palo Alto California, United States, 94301Mercy Cancer Center - Rocklin | Rocklin California, United States, 95765Sutter Roseville Medical Center | Roseville California, United States, 95661Kaiser Permanente Downtown Commons | Sacramento California, United States, 95814Mercy Cancer Center - Sacramento | Sacramento California, United States, 95816Sutter Medical Center Sacramento | Sacramento California, United States, 95816University of California Davis Comprehensive Cancer Center | Sacramento California, United States, 95817Kaiser Permanente Sacramento Medical Center | Sacramento California, United States, 95825California Pacific Medical Center-Pacific Campus | San Francisco California, United States, 94115Kaiser Permanente-San Francisco | San Francisco California, United States, 94115UCSF Medical Center-Mission Bay | San Francisco California, United States, 94158Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo California, United States, 93401Kaiser Permanente Medical Center - Santa Clara | Santa Clara California, United States, 95051Palo Alto Medical Foundation-Santa Cruz | Santa Cruz California, United States, 95065Sutter Pacific Medical Foundation | Santa Rosa California, United States, 95403Palo Alto Medical Foundation-Sunnyvale | Sunnyvale California, United States, 94086Kaiser Permanente-Vallejo | Vallejo California, United States, 94589Kaiser Permanente-Walnut Creek | Walnut Creek California, United States, 94596Woodland Memorial Hospital | Woodland California, United States, 95695UCHealth University of Colorado Hospital | Aurora Colorado, United States, 80045Penrose-Saint Francis Healthcare | Colorado Springs Colorado, United States, 80907UCHealth Memorial Hospital Central | Colorado Springs Colorado, United States, 80909Kaiser Permanente-Franklin | Denver Colorado, United States, 80205Rocky Mountain Cancer Centers-Rose | Denver Colorado, United States, 80220Poudre Valley Hospital | Fort Collins Colorado, United States, 80524UCHealth Highlands Ranch Hospital | Highlands Ranch Colorado, United States, 80129Kaiser Permanente-Rock Creek | Lafayette Colorado, United States, 80026Kaiser Permanente-Lone Tree | Lone Tree Colorado, United States, 80124Danbury Hospital | Danbury Connecticut, United States, 06810Smilow Cancer Hospital Care Center-Fairfield | Fairfield Connecticut, United States, 06824Hartford Hospital | Hartford Connecticut, United States, 06102Smilow Cancer Hospital Care Center at Saint Francis | Hartford Connecticut, United States, 06105Middlesex Hospital | Middletown Connecticut, United States, 06457The Hospital of Central Connecticut | New Britain Connecticut, United States, 06050Yale University | New Haven Connecticut, United States, 06520Norwalk Hospital | Norwalk Connecticut, United States, 06856Smilow Cancer Hospital Care Center-Trumbull | Trumbull Connecticut, United States, 06611Helen F Graham Cancer Center | Newark Delaware, United States, 19713Medical Oncology Hematology Consultants PA | Newark Delaware, United States, 19713Christiana Care Health System-Christiana Hospital | Newark Delaware, United States, 19718Sibley Memorial Hospital | Washington D.C. District of Columbia, United States, 20016UF Health Cancer Institute - Gainesville | Gainesville Florida, United States, 32610Mount Sinai Medical Center | Miami Beach Florida, United States, 33140Orlando Health Cancer Institute | Orlando Florida, United States, 32806Sarasota Memorial Hospital | Sarasota Florida, United States, 34239Emory University Hospital Midtown | Atlanta Georgia, United States, 30308Piedmont Hospital | Atlanta Georgia, United States, 30309Emory University Hospital/Winship Cancer Institute | Atlanta Georgia, United States, 30322Northside Hospital | Atlanta Georgia, United States, 30342Augusta University Medical Center | Augusta Georgia, United States, 30912WellStar Cobb Hospital | Austell Georgia, United States, 30106WellStar Health System Inc | Marietta Georgia, United States, 30060Wellstar Kennestone Hospital | Marietta Georgia, United States, 30060WellStar North Fulton Hospital | Roswell Georgia, United States, 30076Memorial Health University Medical Center | Savannah Georgia, United States, 31404Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah Georgia, United States, 31405WellStar Vinings Health Park | Smyrna Georgia, United States, 30080Queen's Medical Center | Honolulu Hawaii, United States, 96813Kapiolani Medical Center for Women and Children | Honolulu Hawaii, United States, 96826Saint Alphonsus Cancer Care Center-Boise | Boise Idaho, United States, 83706Saint Luke's Cancer Institute - Boise | Boise Idaho, United States, 83712Saint Luke's Cancer Institute - Fruitland | Fruitland Idaho, United States, 83619Saint Luke's Cancer Institute - Meridian | Meridian Idaho, United States, 83642Saint Luke's Cancer Institute - Nampa | Nampa Idaho, United States, 83687Rush-Copley Medical Center | Aurora Illinois, United States, 60504Illinois CancerCare-Bloomington | Bloomington Illinois, United States, 61704Illinois CancerCare-Canton | Canton Illinois, United States, 61520Illinois CancerCare-Carthage | Carthage Illinois, United States, 62321Centralia Oncology Clinic | Centralia Illinois, United States, 62801Northwestern University | Chicago Illinois, United States, 60611John H Stroger Jr Hospital of Cook County | Chicago Illinois, United States, 60612Rush MD Anderson Cancer Center | Chicago Illinois, United States, 60612UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital | Chicago Illinois, United States, 60657Cancer Care Specialists of Illinois - Decatur | Decatur Illinois, United States, 62526Decatur Memorial Hospital | Decatur Illinois, United States, 62526Crossroads Cancer Center | Effingham Illinois, United States, 62401Illinois CancerCare-Eureka | Eureka Illinois, United States, 61530NorthShore University HealthSystem-Evanston Hospital | Evanston Illinois, United States, 60201Illinois CancerCare-Galesburg | Galesburg Illinois, United States, 61401Northwestern Medicine Cancer Center Delnor | Geneva Illinois, United States, 60134NorthShore University HealthSystem-Glenbrook Hospital | Glenview Illinois, United States, 60026NorthShore University HealthSystem-Highland Park Hospital | Highland Park Illinois, United States, 60035Sudarshan K Sharma MD Limited-Gynecologic Oncology | Hinsdale Illinois, United States, 60521Illinois CancerCare-Kewanee Clinic | Kewanee Illinois, United States, 61443Illinois CancerCare-Macomb | Macomb Illinois, United States, 61455Cancer Care Center of O'Fallon | O'Fallon Illinois, United States, 62269Illinois CancerCare-Ottawa Clinic | Ottawa Illinois, United States, 61350Illinois CancerCare-Pekin | Pekin Illinois, United States, 61554Illinois CancerCare-Peoria | Peoria Illinois, United States, 61615Illinois CancerCare-Peru | Peru Illinois, United States, 61354Illinois CancerCare-Princeton | Princeton Illinois, United States, 61356Springfield Clinic | Springfield Illinois, United States, 62702Springfield Memorial Hospital | Springfield Illinois, United States, 62781Northwestern Medicine Cancer Center Warrenville | Warrenville Illinois, United States, 60555Midwestern Regional Medical Center | Zion Illinois, United States, 60099Parkview Regional Medical Center | Fort Wayne Indiana, United States, 46845Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis Indiana, United States, 46202Ascension Saint Vincent Indianapolis Hospital | Indianapolis Indiana, United States, 46260Reid Health | Richmond Indiana, United States, 47374Memorial Hospital of South Bend | South Bend Indiana, United States, 46601Mercy Cancer Center-West Lakes | Clive Iowa, United States, 50325UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive Iowa, United States, 50325Iowa Methodist Medical Center | Des Moines Iowa, United States, 50309UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines Iowa, United States, 50309Mercy Medical Center - Des Moines | Des Moines Iowa, United States, 50314UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines Iowa, United States, 50314University of Iowa/Holden Comprehensive Cancer Center | Iowa City Iowa, United States, 52242Siouxland Regional Cancer Center | Sioux City Iowa, United States, 51101Mercy Medical Center-West Lakes | West Des Moines Iowa, United States, 50266Associates In Womens Health | Wichita Kansas, United States, 67208Ascension Via Christi Hospitals Wichita | Wichita Kansas, United States, 67214Saint Elizabeth Healthcare Edgewood | Edgewood Kentucky, United States, 41017University of Kentucky/Markey Cancer Center | Lexington Kentucky, United States, 40536Hematology/Oncology Clinic PLLC | Baton Rouge Louisiana, United States, 70809Mary Bird Perkins Cancer Center | Baton Rouge Louisiana, United States, 70809Woman's Hospital | Baton Rouge Louisiana, United States, 70817Women's Cancer Care-Covington | Covington Louisiana, United States, 70433Ochsner Medical Center Jefferson | New Orleans Louisiana, United States, 70121Eastern Maine Medical Center | Bangor Maine, United States, 04401Lafayette Family Cancer Center-EMMC | Brewer Maine, United States, 04412MaineHealth Maine Medical Center- Scarborough | Scarborough Maine, United States, 04074Greater Baltimore Medical Center | Baltimore Maryland, United States, 21204MedStar Franklin Square Medical Center/Weinberg Cancer Institute | Baltimore Maryland, United States, 21237Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore Maryland, United States, 21287UM Upper Chesapeake Medical Center | Bel Air Maryland, United States, 21014National Institutes of Health Clinical Center | Bethesda Maryland, United States, 20892TidalHealth Richard A Henson Cancer Institute | Ocean Pines Maryland, United States, 21811TidalHealth Peninsula Regional | Salisbury Maryland, United States, 21801Brigham and Women's Hospital | Boston Massachusetts, United States, 02115Dana-Farber Cancer Institute | Boston Massachusetts, United States, 02215UMass Memorial Medical Center - Memorial Division | Worcester Massachusetts, United States, 01605Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor Michigan, United States, 48106University of Michigan Rogel Cancer Center | Ann Arbor Michigan, United States, 48109Henry Ford Cancer Institute-Downriver | Brownstown Michigan, United States, 48183Henry Ford Macomb Hospital-Clinton Township | Clinton Township Michigan, United States, 48038Wayne State University/Karmanos Cancer Institute | Detroit Michigan, United States, 48201Henry Ford Hospital | Detroit Michigan, United States, 48202OSF Saint Francis Hospital and Medical Group | Escanaba Michigan, United States, 49829Weisberg Cancer Treatment Center | Farmington Hills Michigan, United States, 48334Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids Michigan, United States, 49503West Michigan Cancer Center | Kalamazoo Michigan, United States, 49007University of Michigan Health - Sparrow Lansing | Lansing Michigan, United States, 48912Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac Michigan, United States, 48341Munson Medical Center | Traverse City Michigan, United States, 49684Henry Ford West Bloomfield Hospital | West Bloomfield Michigan, United States, 48322Sanford Joe Lueken Cancer Center | Bemidji Minnesota, United States, 56601Fairview Ridges Hospital | Burnsville Minnesota, United States, 55337Mercy Hospital | Coon Rapids Minnesota, United States, 55433Fairview Southdale Hospital | Edina Minnesota, United States, 55435Mayo Clinic Health Systems-Mankato | Mankato Minnesota, United States, 56001Fairview Clinics and Surgery Center Maple Grove | Maple Grove Minnesota, United States, 55369Saint John's Hospital - Healtheast | Maplewood Minnesota, United States, 55109Abbott-Northwestern Hospital | Minneapolis Minnesota, United States, 55407University of Minnesota/Masonic Cancer Center | Minneapolis Minnesota, United States, 55455Mayo Clinic in Rochester | Rochester Minnesota, United States, 55905Park Nicollet Clinic - Saint Louis Park | Saint Louis Park Minnesota, United States, 55416Regions Hospital | Saint Paul Minnesota, United States, 55101United Hospital | Saint Paul Minnesota, United States, 55102Saint Francis Regional Medical Center | Shakopee Minnesota, United States, 55379Minnesota Oncology Hematology PA-Woodbury | Woodbury Minnesota, United States, 55125University of Mississippi Medical Center | Jackson Mississippi, United States, 39216Saint Francis Medical Center | Cape Girardeau Missouri, United States, 63703MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia Missouri, United States, 65212Mercy Hospital Joplin | Joplin Missouri, United States, 64804Mercy Hospital Springfield | Springfield Missouri, United States, 65804CoxHealth South Hospital | Springfield Missouri, United States, 65807Barnes-Jewish Hospital | St Louis Missouri, United States, 63110Washington University School of Medicine | St Louis Missouri, United States, 63110Billings Clinic Cancer Center | Billings Montana, United States, 59101Bozeman Health Deaconess Hospital | Bozeman Montana, United States, 59715Benefis Sletten Cancer Institute | Great Falls Montana, United States, 59405Nebraska Cancer Specialists/Oncology Hematology West PC | Grand Island Nebraska, United States, 68803CHI Health Good Samaritan | Kearney Nebraska, United States, 68847Nebraska Methodist Hospital | Omaha Nebraska, United States, 68114Alegent Health Bergan Mercy Medical Center | Omaha Nebraska, United States, 68124Alegent Health Lakeside Hospital | Omaha Nebraska, United States, 68130Women's Cancer Center of Nevada | Las Vegas Nevada, United States, 89106Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon New Hampshire, United States, 03756Dartmouth Cancer Center - Nashua | Nashua New Hampshire, United States, 03063Cooper Hospital University Medical Center | Camden New Jersey, United States, 08103Hackensack University Medical Center | Hackensack New Jersey, United States, 07601The Cancer Institute of New Jersey Hamilton | Hamilton New Jersey, United States, 08690Morristown Medical Center | Morristown New Jersey, United States, 07960Jersey Shore Medical Center | Neptune City New Jersey, United States, 07753Rutgers Cancer Institute of New Jersey | New Brunswick New Jersey, United States, 08903Robert Wood Johnson University Hospital Somerset | Somerville New Jersey, United States, 08876Overlook Hospital | Summit New Jersey, United States, 07902MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township New Jersey, United States, 08043Southwest Gynecologic Oncology Associates Inc | Albuquerque New Mexico, United States, 87106University of New Mexico Cancer Center | Albuquerque New Mexico, United States, 87106Memorial Medical Center-Las Cruces | Las Cruces New Mexico, United States, 88011Women's Cancer Care Associates LLC | Albany New York, United States, 12208State University of New York Downstate Medical Center | Brooklyn New York, United States, 11203Roswell Park Cancer Institute | Buffalo New York, United States, 14263Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York New York, United States, 10016University of Rochester | Rochester New York, United States, 14642Stony Brook University Medical Center | Stony Brook New York, United States, 11794State University of New York Upstate Medical University | Syracuse New York, United States, 13210Montefiore Medical Center-Einstein Campus | The Bronx New York, United States, 10461Dickstein Cancer Treatment Center | White Plains New York, United States, 10601AdventHealth Infusion Center Asheville | Asheville North Carolina, United States, 28803UNC Lineberger Comprehensive Cancer Center | Chapel Hill North Carolina, United States, 27599AdventHealth Infusion Center Haywood | Clyde North Carolina, United States, 28721Duke University Medical Center | Durham North Carolina, United States, 27710Southeastern Medical Oncology Center-Goldsboro | Goldsboro North Carolina, United States, 27534Margaret R Pardee Memorial Hospital | Hendersonville North Carolina, United States, 28791AdventHealth Hendersonville | Hendersonville North Carolina, United States, 28792Southeastern Medical Oncology Center-Jacksonville | Jacksonville North Carolina, United States, 28546FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst North Carolina, United States, 28374Duke Cancer Center Raleigh | Raleigh North Carolina, United States, 27609Novant Health New Hanover Regional Medical Center | Wilmington North Carolina, United States, 28401Wake Forest University Health Sciences | Winston-Salem North Carolina, United States, 27157Sanford Bismarck Medical Center | Bismarck North Dakota, United States, 58501Sanford Broadway Medical Center | Fargo North Dakota, United States, 58122Sanford Roger Maris Cancer Center | Fargo North Dakota, United States, 58122Cleveland Clinic Akron General | Akron Ohio, United States, 44307Aultman Health Foundation | Canton Ohio, United States, 44710Miami Valley Hospital South | Centerville Ohio, United States, 45459University of Cincinnati Cancer Center-UC Medical Center | Cincinnati Ohio, United States, 45219Good Samaritan Hospital - Cincinnati | Cincinnati Ohio, United States, 45220TriHealth Cancer Institute-Westside | Cincinnati Ohio, United States, 45247MetroHealth Medical Center | Cleveland Ohio, United States, 44109Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland Ohio, United States, 44111Cleveland Clinic Foundation | Cleveland Ohio, United States, 44195Ohio State University Comprehensive Cancer Center | Columbus Ohio, United States, 43210Riverside Methodist Hospital | Columbus Ohio, United States, 43214The Mark H Zangmeister Center | Columbus Ohio, United States, 43219Grandview Hospital | Dayton Ohio, United States, 45405Orion Cancer Care | Findlay Ohio, United States, 45840Hillcrest Hospital Cancer Center | Mayfield Heights Ohio, United States, 44124ProMedica Flower Hospital | Sylvania Ohio, United States, 43560ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo Ohio, United States, 43606University of Cincinnati Cancer Center-West Chester | West Chester Ohio, United States, 45069Wright-Patterson Medical Center | Wright-Patterson Air Force Base Ohio, United States, 45433University of Oklahoma Health Sciences Center | Oklahoma City Oklahoma, United States, 73104Cancer Treatment Centers of America | Tulsa Oklahoma, United States, 74133Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa Oklahoma, United States, 74146Saint Charles Health System | Bend Oregon, United States, 97701Legacy Mount Hood Medical Center | Gresham Oregon, United States, 97030Legacy Good Samaritan Hospital and Medical Center | Portland Oregon, United States, 97210Legacy Meridian Park Hospital | Tualatin Oregon, United States, 97062Jefferson Abington Hospital | Abington Pennsylvania, United States, 19001Saint Luke's University Hospital-Bethlehem Campus | Bethlehem Pennsylvania, United States, 18015Bryn Mawr Hospital | Bryn Mawr Pennsylvania, United States, 19010Geisinger Medical Center | Danville Pennsylvania, United States, 17822Ephrata Cancer Center | Ephrata Pennsylvania, United States, 17522Ephrata Community Hospital | Ephrata Pennsylvania, United States, 17522Adams Cancer Center | Gettysburg Pennsylvania, United States, 17325WellSpan Medical Oncology and Hematology | Hanover Pennsylvania, United States, 17331UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg Pennsylvania, United States, 17109Sechler Family Cancer Center | Lebanon Pennsylvania, United States, 17042Geisinger Medical Oncology-Lewisburg | Lewisburg Pennsylvania, United States, 17837Paoli Memorial Hospital | Paoli Pennsylvania, United States, 19301University of Pennsylvania/Abramson Cancer Center | Philadelphia Pennsylvania, United States, 19104West Penn Hospital | Pittsburgh Pennsylvania, United States, 15224Guthrie Medical Group PC-Robert Packer Hospital | Sayre Pennsylvania, United States, 18840Reading Hospital | West Reading Pennsylvania, United States, 19611Wexford Health and Wellness Pavilion | Wexford Pennsylvania, United States, 15090UPMC Susquehanna | Williamsport Pennsylvania, United States, 17701Asplundh Cancer Pavilion | Willow Grove Pennsylvania, United States, 19090Lankenau Medical Center | Wynnewood Pennsylvania, United States, 19096WellSpan Health-York Hospital | York Pennsylvania, United States, 17403Women and Infants Hospital | Providence Rhode Island, United States, 02905AnMed Health Cancer Center | Anderson South Carolina, United States, 29621Gibbs Cancer Center-Gaffney | Gaffney South Carolina, United States, 29341Saint Francis Hospital | Greenville South Carolina, United States, 29601Saint Francis Cancer Center | Greenville South Carolina, United States, 29607Gibbs Cancer Center-Pelham | Greer South Carolina, United States, 29651South Carolina Cancer Specialists PC | Hilton Head Island South Carolina, United States, 29926-3827Spartanburg Medical Center | Spartanburg South Carolina, United States, 29303SMC Center for Hematology Oncology Union | Union South Carolina, United States, 29379Rapid City Regional Hospital | Rapid City South Dakota, United States, 57701Sanford Cancer Center Oncology Clinic | Sioux Falls South Dakota, United States, 57104Avera Cancer Institute | Sioux Falls South Dakota, United States, 57105Sanford USD Medical Center - Sioux Falls | Sioux Falls South Dakota, United States, 57117-5134Ballad Health Cancer Care - Kingsport | Kingsport Tennessee, United States, 37660Wellmont Holston Valley Hospital and Medical Center | Kingsport Tennessee, United States, 37660Covenant Health Cancer Centers | Knoxville Tennessee, United States, 37916Covenant Health Cancer Centers - West | Knoxville Tennessee, United States, 37932Vanderbilt University/Ingram Cancer Center | Nashville Tennessee, United States, 37232Parkland Memorial Hospital | Dallas Texas, United States, 75235UT Southwestern/Simmons Cancer Center-Dallas | Dallas Texas, United States, 75390Houston Methodist Hospital | Houston Texas, United States, 77030Methodist Willowbrook Hospital | Houston Texas, United States, 77070Houston Methodist Sugar Land Hospital | Sugar Land Texas, United States, 77479Intermountain Medical Center | Murray Utah, United States, 84107Utah Cancer Specialists-Salt Lake City | Salt Lake City Utah, United States, 84106Huntsman Cancer Institute/University of Utah | Salt Lake City Utah, United States, 84112South Jordan Health Center | South Jordan Utah, United States, 84009Saint George Regional Medical Center | St. George Utah, United States, 84770Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners Vermont, United States, 05602University of Vermont Medical Center | Burlington Vermont, United States, 05401University of Vermont and State Agricultural College | Burlington Vermont, United States, 05405University of Virginia Cancer Center | Charlottesville Virginia, United States, 22908VCU Massey Cancer Center at Stony Point | Richmond Virginia, United States, 23235VCU Massey Comprehensive Cancer Center | Richmond Virginia, United States, 23298PeaceHealth Saint Joseph Medical Center | Bellingham Washington, United States, 98225Swedish Cancer Institute-Edmonds | Edmonds Washington, United States, 98026Kadlec Clinic Hematology and Oncology | Kennewick Washington, United States, 99336Skagit Regional Health Cancer Care Center | Mount Vernon Washington, United States, 98274Skagit Valley Hospital | Mount Vernon Washington, United States, 98274Pacific Gynecology Specialists | Seattle Washington, United States, 98104Fred Hutchinson Cancer Center | Seattle Washington, United States, 98109Swedish Medical Center-First Hill | Seattle Washington, United States, 98122University of Washington Medical Center - Northwest | Seattle Washington, United States, 98133Women's Cancer Center of Seattle | Seattle Washington, United States, 98133University of Washington Medical Center - Montlake | Seattle Washington, United States, 98195Legacy Salmon Creek Hospital | Vancouver Washington, United States, 98686Wenatchee Valley Hospital and Clinics | Wenatchee Washington, United States, 98801West Virginia University Charleston Division | Charleston West Virginia, United States, 25304Edwards Comprehensive Cancer Center | Huntington West Virginia, United States, 25701Monongalia Hospital | Morgantown West Virginia, United States, 26505West Virginia University Healthcare | Morgantown West Virginia, United States, 26506Ascension Saint Elizabeth Hospital | Appleton Wisconsin, United States, 54915Aurora Cancer Care-Southern Lakes VLCC | Burlington Wisconsin, United States, 53105Marshfield Clinic-Chippewa Center | Chippewa Falls Wisconsin, United States, 54729Marshfield Clinic Cancer Center at Sacred Heart | Eau Claire Wisconsin, United States, 54701Aurora Health Center-Fond du Lac | Fond du Lac Wisconsin, United States, 54937Aurora Health Care Germantown Health Center | Germantown Wisconsin, United States, 53022Aurora Cancer Care-Grafton | Grafton Wisconsin, United States, 53024Saint Vincent Hospital Cancer Center Green Bay | Green Bay Wisconsin, United States, 54301Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay Wisconsin, United States, 54303Aurora BayCare Medical Center | Green Bay Wisconsin, United States, 54311Aurora Cancer Care-Kenosha South | Kenosha Wisconsin, United States, 53142Gundersen Lutheran Medical Center | La Crosse Wisconsin, United States, 54601Marshfield Medical Center - Ladysmith | Ladysmith Wisconsin, United States, 54848University of Wisconsin Carbone Cancer Center - University Hospital | Madison Wisconsin, United States, 53792Aurora Bay Area Medical Group-Marinette | Marinette Wisconsin, United States, 54143Saint Vincent Hospital Cancer Center at Marinette | Marinette Wisconsin, United States, 54143Marshfield Medical Center-Marshfield | Marshfield Wisconsin, United States, 54449Ascension Columbia Saint Mary's Hospital Ozaukee | Mequon Wisconsin, United States, 53097Aurora Cancer Care-Milwaukee | Milwaukee Wisconsin, United States, 53209Ascension Columbia Saint Mary's Hospital - Milwaukee | Milwaukee Wisconsin, United States, 53211Aurora Saint Luke's Medical Center | Milwaukee Wisconsin, United States, 53215Medical College of Wisconsin | Milwaukee Wisconsin, United States, 53226Aurora Sinai Medical Center | Milwaukee Wisconsin, United States, 53233Marshfield Medical Center - Minocqua | Minocqua Wisconsin, United States, 54548ProHealth D N Greenwald Center | Mukwonago Wisconsin, United States, 53149ProHealth Oconomowoc Memorial Hospital | Oconomowoc Wisconsin, United States, 53066Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls Wisconsin, United States, 54154Ascension Mercy Hospital | Oshkosh Wisconsin, United States, 54904Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh Wisconsin, United States, 54904Aurora Cancer Care-Racine | Racine Wisconsin, United States, 53406Marshfield Medical Center-Rice Lake | Rice Lake Wisconsin, United States, 54868Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan Wisconsin, United States, 53081Aspirus Cancer Care - Stevens Point | Stevens Point Wisconsin, United States, 54481Marshfield Medical Center-River Region at Stevens Point | Stevens Point Wisconsin, United States, 54482Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay Wisconsin, United States, 54235-1495Aurora Medical Center in Summit | Summit Wisconsin, United States, 53066Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers Wisconsin, United States, 54241ProHealth Waukesha Memorial Hospital | Waukesha Wisconsin, United States, 53188UW Cancer Center at ProHealth Care | Waukesha Wisconsin, United States, 53188Marshfield Clinic-Wausau Center | Wausau Wisconsin, United States, 54401Aurora Cancer Care-Milwaukee West | Wauwatosa Wisconsin, United States, 53226Aurora West Allis Medical Center | West Allis Wisconsin, United States, 53227Marshfield Medical Center - Weston | Weston Wisconsin, United States, 54476Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids Wisconsin, United States, 54494Arthur J E Child Comprehensive Cancer Centre | Calgary Alberta, Canada, T2N 5G2Cross Cancer Institute | Edmonton Alberta, Canada, T6G 1Z2Royal Victoria Regional Health Centre | Barrie Ontario, Canada, L4M 6M2Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton Ontario, Canada, L8V 5C2Kingston Health Sciences Centre | Kingston Ontario, Canada, K7L 2V7London Regional Cancer Program | London Ontario, Canada, N6A 4L6Algoma District Cancer Program Sault Area Hospital | Sault Ste. Marie Ontario, Canada, P6B 0A8Odette Cancer Centre- Sunnybrook Health Sciences Centre | Toronto Ontario, Canada, M4N 3M5University Health Network-Princess Margaret Hospital | Toronto Ontario, Canada, M5G 2M9CIUSSSEMTL-Hopital Maisonneuve-Rosemont | Montreal Quebec, Canada, H1T 2M4CHUM - Centre Hospitalier de l'Universite de Montreal | Montreal Quebec, Canada, H2X 3E4Jewish General Hospital | Montreal Quebec, Canada, H3T 1E2CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) | Québec Quebec, Canada, G1R 2J6Ehime University Hospital | Tōon Ehime, Japan, 791-0295Hokkaido University Hospital | Sapporo Hokkaido, Japan, 060-8648Kagoshima City Hospital | Kagoshima Kagoshima-ken, Japan, 890-8760The Cancer Institute Hospital Of JFCR | Koto-ku Tokyo, Japan, 135-8550Kindai University | Osaka , Japan, 589 8511Saitama Medical University International Medical Center | Saitama , Japan, 350-1298National Cancer Center Hospital | Tokyo , Japan, 104 0045Centro Comprensivo de Cancer de UPR | San Juan , Puerto Rico, 00927Keimyung University-Dongsan Medical Center | Dalseo-gu Daegu, South Korea, 42601Seoul National University Bundang Hospital | Seongnam Kyeonggi-do, South Korea, 463-707Gachon University Gil Hospital | Incheon , South Korea, 405-760Asan Medical Center | Seoul , South Korea, 05505Gangnam Severance Hospital | Seoul , South Korea, 06273Kyung Hee University Hospital at Gangdong | Seoul , South Korea, 134-727Korea Cancer Center Hospital | Seoul , South Korea, 139-706
Investigators
Principal Investigator: Jung-min Lee, NRG Oncology
Study Documents (Full Text)
Documents provided by National Cancer Institute (NCI): Study Protocol and Statistical Analysis Plan  July 26, 2023